IP Library Granted Patent US 10,369,160
Granted Patent B2
US 10,369,160 · App. 15/484,379 · Granted Aug 6, 2019

Methods of treating cancer

Inventors: Antonio Moschetta (Bitonto Bari, IT); Jesus Maria Banales Asurmedi (San Sebastián, ES); Luis Bujanda Fernández de Pierola (San Sebastián, ES); María Jesús Perugorria Montiel (San Sebastián, ES); Oihane Erice Azparren (San Sebastián, ES)
Assignee: Intercept Pharmaceuticals, Inc.
A61K31/575A61K31/133A61K47/54A61K47/542A61P35/00A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,369,160
App. No.
15/484,379
Granted
Aug 6, 2019
Kind
B2
Abstract

The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.

Claims (9)

1. A method of treating or preventing hepatocellular carcinoma in a subject in need thereof comprising administering a therapeutically effective amount of Compound 1:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the hepatocellular carcinoma is selected from the group consisting of early stage hepatocellular carcinoma, non-metastatic hepatocellular carcinoma, primary hepatocellular carcinoma, advanced hepatocellular carcinoma, locally advanced hepatocellular carcinoma, metastatic hepatocellular carcinoma, hepatocellular carcinoma in remission, or recurrent hepatocellular carcinoma.

3. The method of claim 1 , wherein the FXR agonist is the sodium salt of Compound 1.

4. The method of claim 1 , wherein the FXR agonist is the N,N-diethylethaneamine salt of Compound 1.

5. A method of treating or preventing hepatocellular carcinoma in a subject in need thereof comprising administering a pharmaceutical composition comprising a therapeutically effective amount of FXR agonist selected from Compound 1:

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

6. A kit for treating or preventing hepatocellular carcinoma in a subject in need thereof comprising Compound 1:

or a pharmaceutically acceptable salt thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0990 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2019
From: MOSCHETTA, ANTONIO
To: INTERCEPT PHARMACEUTICALS, INC
Reel/Frame 048619/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2019
From: BANALES ASURMENDI, JESUS MARIA; FERNANDEZ DE PIEROLA, LUIS BUJANDA; PERUGORRIA MONTIEL, MARIA JESUS; AZPARREN, OIHANE ERICE
To: INTERCEPT PHARMACEUTICALS, INC
Reel/Frame 048153/0597 →
Continuity (3)
Provisional Application 62321816 · Apr 13, 2016
Provisional Application 62468259 · Mar 7, 2017
Related Publication 20170296556A1 · Oct 19, 2017